Action of the SV40 T Antigen Chaperone Machine on Tumor Suppressors
SV40 T 抗原伴侣机对肿瘤抑制剂的作用
基本信息
- 批准号:7382592
- 负责人:
- 金额:$ 30.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-04-14 至 2011-02-28
- 项目状态:已结题
- 来源:
- 关键词:ATP HydrolysisATP phosphohydrolaseAdoptedAmino AcidsApoptosisBindingBiochemicalBiochemical GeneticsBiologicalCell Cycle RegulationCell ProliferationCell physiologyChemicalsChromatinComplexCrystallizationCrystallographyDNA biosynthesisDataDevelopmentDiscriminationDiseaseDisruptionE2F transcription factorsElevationFamilyFamily memberGene MutationGenesGeneticGenetic TranscriptionGoalsGrowthHomeostasisHomologous GeneHost DefenseIn VitroInfectionLocalizedLocationMalignant NeoplasmsMediatingModelingMolecularMolecular ChaperonesMolecular ConformationOncogene ProteinsParticipantPhosphorylationPlayPliabilityProductionProtein BindingProteinsRBL2 geneReactionRecruitment ActivityRegulationRelaxationResolutionRestRetinoblastomaRetinoblastoma ProteinRoleSignal TransductionSimian virus 40StagingSystemTestingTissuesTranscriptional ActivationTranscriptional RegulationTumor AntigensTumor Suppressor ProteinsViralViral Tumor AntigensVirionVirusVirus DiseasesWorkX-Ray Crystallographyantigen bindingbasegenetic regulatory proteinhuman RBL2 proteinin vivointerestmembermetaplastic cell transformationmutantpromoterresearch studysialosyl-T antigenthree dimensional structuretranscription factor
项目摘要
Tumor suppressors are regulatory proteins that receive and integrate diverse signals and function to
exert control over key cellular processes such as cell proliferation, differentiation, and apoptosis. Because
loss or perturbation of their activity often results in cancer or other diseases, and because of their central role
in governing organismal development and tissue homeostasis, these proteins are of great interest. The
retinoblastoma protein (pRb) is a well characterized tumor suppressor that, in concert with two related
proteins, p130and p107,control cell cycle entry and exit, in part, by regulating the activity of the E2F family
of transcription factors.
Many viruses, including Simian virus 40 (SV40) encode oncoproteins that bind Rb-family members
and interfere with their ability to regulate E2Fs. The large tumor antigen (T antigen) encoded by SV40 binds
to pRb, p107, and p130via an LXCXE motif and blocks the ability of these proteins to inhibit E2F-dependent
transcription and to induce growth arrest. The retinoblastoma family has been studied intensively, yet little is
known about the molecular basis by which viruses, such as SV40, block their action. In fact, interaction with T
antigen has different consequences for each Rb protein. For example, p130 is degraded following SV40
infection or transformation, while the levels of pRb remain unchanged. Thus, T antigen appears to be able to
distinguish different Rb-E2F complexes, but the basis for this discrimination is unknown.
Like many regulatory proteins pRb and E2F transcription factors do not exist in isolation. Rather they
function as part of large multiprotein assemblages that include chromatin modifiers, the basal transcription
apparatus, as well as other factors, and the dynamic assembly and disassembly of these complexes is critical
to their regulation. T antigen has a J domain and has been shown to function as a DnaJ molecular
chaperone. The J domain is required for a vital DNA replication, transcriptional control, and virion assembly.
Importantly, the J domain is required for T antigen to block the function of Rb proteins and thus to activate
E2F-dependent transcription. This application seeks to understand the mechanistic and structural basis for
the action of T antigen's recognition and disruption of Rb-E2F complexes.' First, biochemical studies will
explore the ability of the T antigen chaperone machine to distinguish and act upon p130-E2F4-DP1, pRb-
E2F4-DP1, and pRb-E2F1-DP1 complexes. Second, the role of J domain orientation and flexibility will be
examined using a combination of NMR and X-ray crystallography. Finally, a combined genetic and
biochemical approach will be used to identify additional protein participants in the chaperone reaction. These
studies will enhance our understanding of how these tumor suppressors govern cell proliferation and survival,
and how subversion of these mechanisms by viruses or genetic mutation, contribute to cancer.
抑制肿瘤是调节蛋白,接收并整合多种信号和功能到
对关键细胞过程(例如细胞增殖,分化和凋亡)发挥控制。因为
其活动的丧失或扰动通常会导致癌症或其他疾病,并且由于其核心作用
在管理生物体发育和组织稳态时,这些蛋白质引起了极大的兴趣。这
视网膜母细胞瘤蛋白(PRB)是一种特征良好的肿瘤抑制剂,与两个相关的肿瘤抑制剂
蛋白质,P130和P107,控制细胞周期的进入和出口,部分通过调节E2F家族的活性
转录因子。
许多病毒,包括结合RB家族成员
并干扰他们调节E2F的能力。由SV40编码的大肿瘤抗原(T抗原)结合
对于PRB,P107和P130VIA A lxCXE基序,并阻止这些蛋白抑制E2F依赖性的能力
转录并引起生长停滞。视网膜母细胞瘤家族已经进行了深入的研究,但几乎没有
关于病毒(例如SV40)阻止其作用的分子基础已知。实际上,与t的互动
抗原对每种RB蛋白都有不同的后果。例如,SV40后P130降解
感染或转化,而PRB的水平保持不变。因此,T抗原似乎能够
区分不同的RB-E2F复合物,但是这种歧视的基础尚不清楚。
像许多调节蛋白一样,PRB和E2F转录因子不存在。而是他们
功能是包括染色质修饰剂的大型多蛋白组合的一部分,基础转录
设备以及其他因素以及这些复合物的动态组装和拆卸是至关重要的
对他们的监管。 T抗原具有J结构域,已被证明充当DNAJ分子
伴侣。 J域是重要的DNA复制,转录控制和病毒体组件所必需的。
重要的是,t抗原需要阻断RB蛋白的功能,从而激活J域需要J结构域
E2F依赖性转录。该应用程序旨在了解
T抗原识别和破坏RB-E2F复合物的作用。首先,生化研究将
探索T抗原伴侣机的能力区分和作用于P130-E2F4-DP1,PRB-
E2F4-DP1和PRB-E2F1-DP1复合物。其次,J域取向和灵活性的作用将是
使用NMR和X射线晶体学的组合检查。最后,一个遗传和
生化方法将用于鉴定伴侣反应中的其他蛋白质参与者。这些
研究将增强我们对这些肿瘤抑制剂如何控制细胞增殖和生存的理解,
以及这些机制如何通过病毒或遗传突变颠覆,导致癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES M PIPAS其他文献
JAMES M PIPAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES M PIPAS', 18)}}的其他基金
Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
- 批准号:
10401454 - 财政年份:2020
- 资助金额:
$ 30.75万 - 项目类别:
Analysis of cellular factors limiting productive JC virus infections
限制生产性 JC 病毒感染的细胞因素分析
- 批准号:
10312804 - 财政年份:2020
- 资助金额:
$ 30.75万 - 项目类别:
Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
- 批准号:
10030247 - 财政年份:2020
- 资助金额:
$ 30.75万 - 项目类别:
Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
- 批准号:
10196991 - 财政年份:2020
- 资助金额:
$ 30.75万 - 项目类别:
Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
- 批准号:
10621762 - 财政年份:2020
- 资助金额:
$ 30.75万 - 项目类别:
Exploring viral infection with single cell transcriptomics
用单细胞转录组学探索病毒感染
- 批准号:
9285734 - 财政年份:2016
- 资助金额:
$ 30.75万 - 项目类别:
Regulation of cellular functions by two human Polyomaviruses
两种人类多瘤病毒对细胞功能的调节
- 批准号:
9088664 - 财政年份:2016
- 资助金额:
$ 30.75万 - 项目类别:
Exploring viral infection with single cell transcriptomics
用单细胞转录组学探索病毒感染
- 批准号:
9167182 - 财政年份:2016
- 资助金额:
$ 30.75万 - 项目类别:
Regulation of Transcription and Translation by Human Polyomaviruses
人类多瘤病毒的转录和翻译调控
- 批准号:
8849838 - 财政年份:2014
- 资助金额:
$ 30.75万 - 项目类别:
Regulation of Transcription and Translation by Human Polyomaviruses
人类多瘤病毒的转录和翻译调控
- 批准号:
8768850 - 财政年份:2014
- 资助金额:
$ 30.75万 - 项目类别:
相似海外基金
Molecular Mechanisms of The Human Mitochondrial ABC Transporter ABCB10
人类线粒体 ABC 转运蛋白 ABCB10 的分子机制
- 批准号:
10596638 - 财政年份:2022
- 资助金额:
$ 30.75万 - 项目类别:
Impact of dilated cardiomyopathy mutations on cardiac myosin structure and function
扩张型心肌病突变对心肌肌球蛋白结构和功能的影响
- 批准号:
10595237 - 财政年份:2022
- 资助金额:
$ 30.75万 - 项目类别:
Dissecting the unique chaperone mechanism of the Rvb1/Rvb2 AAA+ ATPase complex
剖析 Rvb1/Rvb2 AAA ATPase 复合物的独特伴侣机制
- 批准号:
10395443 - 财政年份:2021
- 资助金额:
$ 30.75万 - 项目类别:
Structure and function of mitochondrial Hsp60
线粒体 Hsp60 的结构和功能
- 批准号:
10406155 - 财政年份:2021
- 资助金额:
$ 30.75万 - 项目类别:
Mechanisms of Substrate Selectivity and Transport by a Bacterial Methionine ABC Importer
细菌蛋氨酸 ABC 导入器的底物选择性和运输机制
- 批准号:
10334110 - 财政年份:2021
- 资助金额:
$ 30.75万 - 项目类别: